Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Combined With IMRT and Cisplatin in Nasopharyngeal Carcinoma
NCT00700440Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2008
- Primary completion
- Apr 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Loco-regional Control at 3 months. Started Jul 2008; status: completed.
02
Drugs
cetuximab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00700440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00700440.